PE20142324A1 - Composicion farmaceutica para el tratamiento de incontinencia urinaria y enuresis - Google Patents

Composicion farmaceutica para el tratamiento de incontinencia urinaria y enuresis

Info

Publication number
PE20142324A1
PE20142324A1 PE2014001275A PE2014001275A PE20142324A1 PE 20142324 A1 PE20142324 A1 PE 20142324A1 PE 2014001275 A PE2014001275 A PE 2014001275A PE 2014001275 A PE2014001275 A PE 2014001275A PE 20142324 A1 PE20142324 A1 PE 20142324A1
Authority
PE
Peru
Prior art keywords
enuresis
treatment
pharmaceutical composition
urinary incontinence
composition
Prior art date
Application number
PE2014001275A
Other languages
English (en)
Inventor
Agusti Juan Carlos Llobregat
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of PE20142324A1 publication Critical patent/PE20142324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE FLAVONOIDES ENTRE EL 0,5% A 20% EN PESO, TANINOS CONDENSADOS O PROANTOCIANIDINAS ENTRE EL 2% A 20% EN PESO Y ACIDO GAMMA-AMINOBUTIRICO (GABA) ENTRE EL 0,3% A 60% EN PESO, SOBRE EL TOTAL DE LA COMPOSICION. TAMBIEN PUEDE COMPRENDER DESDE 50% DE UN EXTRACTO DE HUMULUS LUPULUS Y VITAMINAS E Y B. DICHA COMPOSICION SE PRESENTA BAJO LA FORMA DE LIQUIDO INHALABLE, PARCHE, COMPRIMIDO, CAPSULA, INYECTABLE Y/O GEL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA INCONTINENCIA URINARIA Y ENURESIS
PE2014001275A 2012-02-15 2013-01-22 Composicion farmaceutica para el tratamiento de incontinencia urinaria y enuresis PE20142324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Publications (1)

Publication Number Publication Date
PE20142324A1 true PE20142324A1 (es) 2015-01-16

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001275A PE20142324A1 (es) 2012-02-15 2013-01-22 Composicion farmaceutica para el tratamiento de incontinencia urinaria y enuresis

Country Status (20)

Country Link
US (1) US9272011B2 (es)
EP (1) EP2815755A4 (es)
JP (1) JP6203761B2 (es)
KR (1) KR20140127874A (es)
CN (1) CN104254338B (es)
AU (1) AU2013220284A1 (es)
BR (1) BR112014020154A8 (es)
CA (1) CA2864426A1 (es)
CL (1) CL2014002128A1 (es)
CO (1) CO7141408A2 (es)
CR (1) CR20140419A (es)
EA (1) EA028184B1 (es)
ES (1) ES2423254B1 (es)
IL (1) IL233978A0 (es)
MA (1) MA37324A1 (es)
MX (1) MX367671B (es)
PE (1) PE20142324A1 (es)
PH (1) PH12014501823A1 (es)
WO (1) WO2013121061A1 (es)
ZA (1) ZA201406668B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2002541198A (ja) * 1999-04-08 2002-12-03 ワーナー−ランバート・カンパニー 失禁の治療法
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
CN1867327A (zh) * 2003-09-11 2006-11-22 什诺波特有限公司 使用gaba类似物的前药治疗和/或预防尿失禁
NZ546138A (en) * 2003-10-09 2009-12-24 Pacific Arrow Ltd Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
KR20140127874A (ko) 2014-11-04
US20150044308A1 (en) 2015-02-12
IL233978A0 (en) 2014-09-30
MX367671B (es) 2019-08-30
CR20140419A (es) 2014-11-28
US9272011B2 (en) 2016-03-01
WO2013121061A1 (es) 2013-08-22
CA2864426A1 (en) 2013-08-22
BR112014020154A8 (pt) 2017-07-11
PH12014501823A1 (en) 2014-11-24
AU2013220284A1 (en) 2014-09-25
MA37324A1 (fr) 2016-03-31
JP2015507002A (ja) 2015-03-05
CL2014002128A1 (es) 2015-03-13
CN104254338A (zh) 2014-12-31
CN104254338B (zh) 2019-05-31
ZA201406668B (en) 2016-05-25
EA201491437A1 (ru) 2015-06-30
BR112014020154A2 (es) 2017-06-20
ES2423254A1 (es) 2013-09-18
CO7141408A2 (es) 2014-12-12
EA028184B1 (ru) 2017-10-31
EP2815755A1 (en) 2014-12-24
JP6203761B2 (ja) 2017-09-27
EP2815755A4 (en) 2015-08-05
MX2014009464A (es) 2014-11-12
ES2423254B1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
HRP20201506T1 (hr) Uporaba kanabidiolne kiseline u liječenju epilepsije
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
CO2019001043A2 (es) Composición de cannabis
NZ726746A (en) Stable cannabinoid formulations
AR078247A1 (es) Vacuna de pcsk9
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CL2012002893A1 (es) Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales.
PE20142324A1 (es) Composicion farmaceutica para el tratamiento de incontinencia urinaria y enuresis
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
BR112015023872A2 (pt) composição compreendendo arabinogalactano e poliofenóis de árvores de lariço
EA201490478A1 (ru) Способ получения сухих экстрактов
HN2010001125A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT201500189A (es) Inhibidores de autotaxina
TH134923A (th) องค์ประกอบสำหรับช่องปากซึ่งมีสิ่งสกัด Garcinia mangostana L. และวิธีที่เกี่ยวข้อง
MY187299A (en) An extract of tinospora crispa and use as an antihypercholesterolemic agent
DOP2012000097A (es) Dispositivo multidosificador para administrar una dosis a paciente
TH137276A (th) ไฟโตแคนนาบินอยด์ในการรักษามะเร็ง

Legal Events

Date Code Title Description
FA Abandonment or withdrawal